Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There is discrepancy of results among various individual and me-ta-analytical studies about the effect of metformin on cancer risk and patients' survival. Therefore, we have conducted a comprehensive, updated meta-analysis to evaluate the preventive and therapeutic effects of metformin for cancer patients, as well as the inci-dence of adverse reactions, among metformin users.
Methods: A total of 18 studies (10 cohort studies and 8 randomized controlled trials) in-volving 1,300,820 participants from Europe, North America, and Asia were included in this meta-analysis.
Results: No significant association was found between metformin use and overall survival (Hazard ratio = 1.02; 95% CI, 0.80 - 1.30) and progressive-free survival (Hazard ratio = 1.00; 95% CI, 0.76 - 1.31). In addition, the summary risk estimates for adverse reactions of metformin were not statistically significant between intervention and control groups (Risk Ratio = 1.11; 95% CI, 0.94 - 1.31). However, metformin use was associated with a reduction in cancer risk (Hazard ratio = 0.90, 95% CI, 0.86 - 0.94).
Conclusion: Metformin does not significantly prolong the overall survival and progressive-free survival of cancer patients, but it may effectively reduce the risk of cancer occurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0115680096345507241030224210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol.
Eur Urol
September 2025
Department of Urology, Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Electronic address:
Epigenetic dysregulation of energy homeostasis drives aortic valve stenosis that is treatable with metformin.
JCI Insight
September 2025
Division of Cardiovascular Medicine, Department of Medicine.
Aortic valve stenosis is a progressive and increasingly prevalent disease in older adults, with no approved pharmacologic therapies to prevent or slow its progression. Although genetic risk factors have been identified, the contribution of epigenetic regulation remains poorly understood. Here, we demonstrated that histone deacetylase 3 (HDAC3) maintains aortic valve structure by suppressing mitochondrial biogenesis and preserving extracellular matrix integrity in valvular interstitial fibroblasts.
View Article and Find Full Text PDFCorrigendum to "An injectable and pH-responsive hyaluronic acid hydrogel as metformin carrier for prevention of breast cancer recurrence" [Carbohydr. Polym. 304 (2023): 120493].
Carbohydr Polym
November 2025
Department of Materials Science and Engineering, Engineering Research Center of Artificial Organs and Materials, Jinan University, Guangzhou 510632, PR China. Electronic address:
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
Clin Cancer Res
September 2025
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Purpose: Pretreatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify prespecified biomarkers associated with response to the regimen of paclitaxel, the anti-type I insulin-like growth factor receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared with control therapy (paclitaxel followed by AC). The primary endpoint of this trial is pathologic complete response (pCR).
Experimental Design: One hundred six patients treated with PGM and 119 contemporary controls were evaluated using laser capture microdissection and reverse-phase protein array to evaluate 32 prespecified potential predictive biomarkers in the IGF-1R pathway and 109 additional exploratory endpoints.
Antitumor Effects of Metformin in Squamous Cell Carcinoma under Leptin Treatment Conditions.
Prev Nutr Food Sci
August 2025
Department of Anatomy, Chonnam National University Medical School, Jeonnam 58128, Korea.
Sinonasal squamous cell carcinoma (SNSCC) is a rare, aggressive malignancy with poor clinical outcomes. Metabolic syndrome components, including obesity-associated hyperleptinemia, may promote tumor progression. Leptin is an adipokine that is elevated in obesity and activates oncogenic pathways that drive cancer cell proliferation.
View Article and Find Full Text PDF